» Articles » PMID: 15943631

Patient Survival Following Renal Transplant Failure in Canada

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2005 Jun 10
PMID 15943631
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Studies from the United States have shown that renal allograft failure is associated with a high mortality rate. The purpose of this study was to determine whether transplant failure was associated with survival in a recent cohort of kidney transplant recipients with different characteristics and a distinct health care system from the United States. Cox regression was used to model allograft loss as a time-dependent variable with patient survival as the primary outcome in 4743 kidney transplant recipients from the Canadian Organ Replacement Register. During follow-up 607 (12.8%) patients had allograft failure and 411 (8.7%) died. Patients with a functioning transplant had an unadjusted death rate of 2.06 per 100 patient years that increased to 5.14 per 100 patient years following allograft failure. After controlling for important confounding variables, allograft failure was found to increase the risk of death by over threefold compared to patients who maintained transplant function (adjusted hazard ratio, 3.39; 95% CI, 2.75-4.16; p < 0.0001). In conclusion, this analysis has shown that kidney transplant failure is an independent predictor of mortality following renal transplantation in a Canadian population. This finding supports the premise that it is the loss of transplant function, rather than patient or system-related issues, that is the main factor contributing to outcome.

Citing Articles

Clinical relevance of HLA-DQ eplet mismatch and maintenance immunosuppression with risk of allosensitization after kidney transplant failure.

Tran J, Alrajhi I, Chang D, Sherwood K, Keown P, Gill J Front Genet. 2024; 15:1383220.

PMID: 38638120 PMC: 11024336. DOI: 10.3389/fgene.2024.1383220.


Can We Predict Graft Intolerance Syndrome After Kidney Transplant Failure? External Validation of a Previously Developed Model.

Bunthof K, Saboerali K, van de Wetering J, Nurmohamed A, Bemelman F, Zuilen A Transpl Int. 2023; 36:11147.

PMID: 37213489 PMC: 10195885. DOI: 10.3389/ti.2023.11147.


Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.

Nickerson P, Bohmig G, Chadban S, Kumar D, Mannon R, van Gelder T Trials. 2022; 23(1):1042.

PMID: 36550562 PMC: 9772593. DOI: 10.1186/s13063-022-06897-3.


Effect of kidney replacement therapy modality after first kidney graft failure on second kidney transplantation outcomes.

Couceiro C, Rama I, Comas J, Montero N, Manonelles A, Codina S Clin Kidney J. 2022; 15(11):2046-2055.

PMID: 36325006 PMC: 9613432. DOI: 10.1093/ckj/sfac155.


Revisiting maintenance immunosuppression in patients with renal transplant failure: early weaning of immunosuppression versus prolonged maintenance-systematic review and meta-analysis.

Elgenidy A, Shemies R, Atef M, Awad A, El-Leithy H, Helmy M J Nephrol. 2022; 36(2):537-550.

PMID: 36109426 DOI: 10.1007/s40620-022-01458-y.